Page last updated: 2024-11-06

gemfibrozil 1-o-acylglucuronide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

gemfibrozil 1-O-acylglucuronide: urinary metabolite of gemfibrozil; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID88127
CHEMBL ID2181817
MeSH IDM0248642

Synonyms (28)

Synonym
91683-38-4
gemfibrozil 1-o-acylglucuronide
1-o-gemfibrozil-beta-d-glucuronide
(2s,3s,4s,5r,6s)-6-[5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoyl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
beta-d-glucopyranuronic acid, 1-(5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoate)
unii-954f30wz3y
954f30wz3y ,
chembl2181817 ,
bdbm50397663
gemfibrozil 1-o-beta-glucuronide
gemfibrozil 1-o-|a-glucuronide
gemfibrozil glucuronide
AKOS027324600
gemfibrozil 1-o-??-glucuronide
.beta.-d-glucopyranuronic acid, 1-(5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoate)
gemfibrozil 1-o-.beta.-glucuronide
gemfibrozil acyl-beta-d-glucuronide
DTXSID90919591
1-o-[5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoyl]hexopyranuronic acid
HY-129993
CS-0108995
C90322
(2s,3s,4s,5r,6s)-6-((5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoyl)oxy)-3,4,5-trihydroxytetrahydro-2h-pyran-2-carboxylic acid
MS-27521
gemfibrozil 1-o-?-glucuronide (contains up to 15% ? isomer)
1-[5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoate] beta-d-glucopyranuroic acid
gemfibrozil 1-o- beta -glucuronide
gemfibrozil 1-o--glucuronide

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Furthermore, there were no statistically significant differences in the peak plasma concentration, time of peak concentration, or elimination half-life of zafirlukast between the phases."( The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast.
Backman, JT; Karonen, T; Neuvonen, PJ, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
"Crude GG was extracted from the urine of volunteers dosed with 600 mg of gemfibrozil, and this material was then purified by reversed-phase high-performance liquid chromatography to yield a white solid."( Self-micellization of gemfibrozil 1-O-beta acyl glucuronide in aqueous solution.
Charman, WN; Prankerd, RJ; Scanlon, MJ; Shackleford, DM, 2003
)
0.32
" We studied the effect of dosing interval on the extent of the gemfibrozil-repaglinide interaction."( The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo.
Backman, JT; Kalliokoski, A; Laitila, J; Neuvonen, M; Neuvonen, PJ; Niemi, M; Tornio, A, 2008
)
0.35
" Thus, a strong CYP2C8 inhibitory effect persisted even after gemfibrozil and gemfibrozil 1-O-beta-glucuronide concentrations had decreased to less than 1% of their maximum (24-h dosing interval)."( CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
Backman, JT; Honkalammi, J; Kurkinen, KJ; Neuvonen, M; Neuvonen, PJ; Niemi, M; Tornio, A, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 2C8Homo sapiens (human)IC50 (µMol)28.00000.00081.88487.9000AID705607
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
lipid hydroxylationCytochrome P450 2C8Homo sapiens (human)
organic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C8Homo sapiens (human)
steroid metabolic processCytochrome P450 2C8Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C8Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C8Homo sapiens (human)
retinol metabolic processCytochrome P450 2C8Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
oxidative demethylationCytochrome P450 2C8Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 2C8Homo sapiens (human)
iron ion bindingCytochrome P450 2C8Homo sapiens (human)
protein bindingCytochrome P450 2C8Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C8Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C8Homo sapiens (human)
aromatase activityCytochrome P450 2C8Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
heme bindingCytochrome P450 2C8Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneCytochrome P450 2C8Homo sapiens (human)
plasma membraneCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
cytoplasmCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID1450599Inhibition of CYP2C8 in human liver microsomes using paclitaxel as substrate preincubated for 2 to 40 mins followed by NADPH-generating system addition measured after 2 mins2017Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21
Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8).
AID705608Time dependent inhibition of CYP2C8 in human liver microsomes2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
AID1450598Inhibition of CYP2C8 in human liver microsomes using paclitaxel as substrate after 5 mins2017Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21
Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8).
AID1450597Inhibition of CYP2C8 in human liver microsomes using paclitaxel as substrate preincubated for 30 mins in presence of NADPH-generating system followed by substrate addition measured after 5 mins2017Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21
Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8).
AID705587Inhibition of CYP2C8 in human liver microsomes in presence of NADPH2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
AID705609Plasma concentration in human after 12 hrs2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
AID1450600Inhibition of CYP2C8 in human liver microsomes using paclitaxel as substrate preincubated for 2 to 40 mins measured after 2 mins2017Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21
Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8).
AID705607Inhibition of CYP2C82012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (23.53)18.2507
2000's7 (41.18)29.6817
2010's6 (35.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.41 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (29.41%)5.53%
Reviews3 (17.65%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (52.94%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]